Cardiovascular

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 diabetes, heart disease, nonalcoholic liver disease, and gout.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.

The health equity impact of the polypill is significant; by effectively controlling cardiovascular disease (CVD) risk factors in populations with limited health care access, there's potential to reduce income- and race-related health disparities.

Americans who drank coffee in the morning had a lower overall mortality compared with those who drank coffee later in the day.

Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, continues his discussion on treatment approaches for patients with cardiovascular-kidney-metabolic (CKM) syndrome.

This year's top 5 most-read cardiovascular articles explored topics ranging from FDA approvals to the risks associated with the sugar alcohol xylitol and beyond.

Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the interconnected condition of cardiovascular-kidney-metabolic (CKM) syndrome, which includes obesity, diabetes, chronic kidney disease, and cardiovascular disease.

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights and highlighted promising treatments.

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

Study identifies underutilization of testing, with disparities by race and sex.

Using direct oral anticoagulants as a case study, the authors examined how delayed adoption of novel treatments could impact patient health outcomes and cost.

The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Robert Kushner, MD, MS, and Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, as well as coverage on multiple areas of cardiovascular medicine.

Data presented at the 2024 American Heart Association (AHA) Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

Metformin and lifestyle changes show no significant impact on atrial fibrillation (AFib) burden or progression compared with standard care.

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete stabilization of transthyretin (TTR).

Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.

Evidence highlights the predictive value of the stress hyperglycemia ratio for mortality risk in patients with acute myocardial infarction, ischemic stroke, and acute heart failure.

New study findings reveal that the risk of cardiovascular disease among light ex-smokers aligns quickly with never-smokers, while heavy ex-smokers may take over 25 years to reach the same level.

A new study has linked work-related stress to poorer cardiovascular health, highlighting the need for workplace wellness programs to reduce the risk of cardiovascular disease.

A new study assesses the prognostic accuracy of Predicting Risk of CVD EVENTs (PREVENT) equations for predicting cardiovascular disease (CVD) mortality in the US population.